Title |
Monitoring cancer stem cells: insights into clinical oncology
|
---|---|
Published in |
OncoTargets and therapy, February 2016
|
DOI | 10.2147/ott.s96645 |
Pubmed ID | |
Authors |
ShuChen Lin, YingChun Xu, ZhiHua Gan, Kun Han, HaiYan Hu, Yang Yao, MingZhu Huang, DaLiu Min |
Abstract |
Cancer stem cells (CSCs) are a small, characteristically distinctive subset of tumor cells responsible for tumor initiation and progression. Several treatment modalities, such as surgery, glycolytic inhibition, driving CSC proliferation, immunotherapy, and hypofractionated radiotherapy, may have the potential to eradicate CSCs. We propose that monitoring CSCs is important in clinical oncology as CSC populations may reflect true treatment response and assist with managing treatment strategies, such as defining optimal chemotherapy cycles, permitting pretreatment cancer surveillance, conducting a comprehensive treatment plan, modifying radiation treatment, and deploying rechallenge chemotherapy. Then, we describe methods for monitoring CSCs. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 26% |
Student > Ph. D. Student | 6 | 26% |
Researcher | 4 | 17% |
Other | 2 | 9% |
Student > Master | 2 | 9% |
Other | 2 | 9% |
Unknown | 1 | 4% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 30% |
Biochemistry, Genetics and Molecular Biology | 4 | 17% |
Agricultural and Biological Sciences | 3 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
Chemistry | 2 | 9% |
Other | 4 | 17% |
Unknown | 1 | 4% |